Chemesis’ Subsidiary Natural Ventures Receives Awards for Best Topical, Best Tincture, & Best Vaporizer
Chemesis International Inc. (CSE:CSI) (OTC:CADMF) (FRA:CWAA) (the “Company” or “Chemesis”), announces it subsidiary Natural Ventures has been awarded best topical, best tincture, and best vaporizer at a gala held in Puerto Rico that recognizes industry leaders. The gala was held by the FreeJuana Foundation, a non-profit organization dedicated to the education and responsible use of cannabis and its medicinal benefits.
The FreeJuana Foundation is the first and largest pro-cannabis foundation in Puerto Rico, and it also holds an annual march that helps raise awareness of the benefits of cannabis use. In addition, the group helps bring together experts and policy makers to help shape regulations in Puerto Rico. The Foundation held a gala where over 45 companies participated to recognize those that are committed to their patients and developing the cannabis industry in Puerto Rico, these awards were given through a survey that is conducted among dispensary owners, industry leaders and certified patients of medical cannabis.
“We are extremely honoured to have received such high recognition for our continued dedication to producing products that are of the highest quality,” said CEO of Chemesis, Edgar Montero. “Receiving this recognition through a survey of our peers is validation that our team has developed the right approach to producing our finished goods. Chemesis will continue to employ these strategies and maintain its consistency in all areas of our business.”
On Behalf of The Board of Directors
CEO and Director
About Chemesis International Inc.
Chemesis International Inc. is a vertically integrated global leader in the cannabis industry, currently operating within California, Puerto Rico, and Colombia.
Chemesis is developing a strong foothold in key markets, from cultivation, to manufacturing, distribution and retail. Chemesis has facilities in both Puerto Rico and California, allowing for cost effective production and distribution of its products. In addition, Chemesis leverages exclusive brands and partnerships and uses the highest quality extraction methods to provide consumers with quality cannabis products.
Chemesis will add shareholder value by exploring opportunities in emerging markets while consistently delivering quality product to its consumers from seed to sale.
1 (604) 398-3378
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the transactions contemplated by the Agreement and the Company’s business, products and future of the Company’s business, its expansion plans, product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements, including, among other things, the risks that the transactions contemplated by the Agreement will not complete as anticipated, or at all, that the Company’s products and plans, particularly with respect to expansion into retail and other opportunities, will vary from those stated in this news release, that the anticipated benefits of the proposed alliance with GSRX will not materialize as expected, or at all, and that the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release